CA2201628A1 - Parenteral pharmaceutical compositions containing gf120918a - Google Patents

Parenteral pharmaceutical compositions containing gf120918a

Info

Publication number: CA2201628A1
Authority: CA; Canada
Prior art keywords: pharmaceutical composition; composition according; safe; effective amount; group
Prior art date: 1994-10-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002201628A

Other languages

English (en)

French (fr)

Inventor

Wei-Qin Tong

Mickey Lee Wells

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SmithKline Beecham Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-05

Filing date

1995-10-04

Publication date

1996-04-18

1995-10-04 Application filed by Individual filed Critical Individual

1996-04-18 Publication of CA2201628A1 publication Critical patent/CA2201628A1/en

Status Abandoned legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
239000004094 surface-active agent Substances 0.000 claims abstract description 18
238000001802 infusion Methods 0.000 claims abstract description 13
238000002347 injection Methods 0.000 claims abstract description 11
239000007924 injection Substances 0.000 claims abstract description 11
238000001556 precipitation Methods 0.000 claims abstract description 11
150000003839 salts Chemical class 0.000 claims abstract description 9
239000012453 solvate Substances 0.000 claims abstract description 9
239000003937 drug carrier Substances 0.000 claims abstract description 5
239000000203 mixture Substances 0.000 claims description 50
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
-1 polyoxyethylene Polymers 0.000 claims description 15
239000000872 buffer Substances 0.000 claims description 13
150000001875 compounds Chemical class 0.000 claims description 12
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
239000008121 dextrose Substances 0.000 claims description 11
238000000034 method Methods 0.000 claims description 10
239000008215 water for injection Substances 0.000 claims description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
239000003085 diluting agent Substances 0.000 claims description 9
206010028980 Neoplasm Diseases 0.000 claims description 8
239000002202 Polyethylene glycol Substances 0.000 claims description 8
229920001223 polyethylene glycol Polymers 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
230000036457 multidrug resistance Effects 0.000 claims description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
229920001214 Polysorbate 60 Polymers 0.000 claims description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
239000006184 cosolvent Substances 0.000 claims description 4
239000005022 packaging material Substances 0.000 claims description 4
229920001983 poloxamer Polymers 0.000 claims description 4
SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
229910019142 PO4 Inorganic materials 0.000 claims description 3
239000004359 castor oil Substances 0.000 claims description 3
235000019438 castor oil Nutrition 0.000 claims description 3
235000014113 dietary fatty acids Nutrition 0.000 claims description 3
229930195729 fatty acid Natural products 0.000 claims description 3
239000000194 fatty acid Substances 0.000 claims description 3
229930195712 glutamate Natural products 0.000 claims description 3
235000011187 glycerol Nutrition 0.000 claims description 3
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
229940072106 hydroxystearate Drugs 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
239000010452 phosphate Substances 0.000 claims description 3
230000035945 sensitivity Effects 0.000 claims description 3
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 3
CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 claims description 2
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 2
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 2
229940035676 analgesics Drugs 0.000 claims description 2
239000000730 antalgic agent Substances 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
229940088710 antibiotic agent Drugs 0.000 claims description 2
239000000935 antidepressant agent Substances 0.000 claims description 2
229940005513 antidepressants Drugs 0.000 claims description 2
239000003443 antiviral agent Substances 0.000 claims description 2
229940121357 antivirals Drugs 0.000 claims description 2
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 2
229960001076 chlorpromazine Drugs 0.000 claims description 2
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 2
229960004242 dronabinol Drugs 0.000 claims description 2
RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims description 2
229960000394 droperidol Drugs 0.000 claims description 2
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 2
229960004503 metoclopramide Drugs 0.000 claims description 2
GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 claims description 2
229960002967 nabilone Drugs 0.000 claims description 2
229960000762 perphenazine Drugs 0.000 claims description 2
229960000502 poloxamer Drugs 0.000 claims description 2
WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims description 2
229960003111 prochlorperazine Drugs 0.000 claims description 2
OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 claims description 2
239000008227 sterile water for injection Substances 0.000 claims description 2
XCTYLCDETUVOIP-UHFFFAOYSA-N thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 claims description 2
229960004869 thiethylperazine Drugs 0.000 claims description 2
FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 claims description 2
229960004161 trimethobenzamide Drugs 0.000 claims description 2
239000008186 active pharmaceutical agent Substances 0.000 claims 4
229940088679 drug related substance Drugs 0.000 claims 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
239000004480 active ingredient Substances 0.000 claims 2
229940125665 acridine carboxamide Drugs 0.000 claims 1
150000005215 alkyl ethers Chemical class 0.000 claims 1
230000000767 anti-ulcer Effects 0.000 claims 1
235000019441 ethanol Nutrition 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
235000013772 propylene glycol Nutrition 0.000 claims 1
239000008174 sterile solution Substances 0.000 claims 1
229960003904 triflupromazine Drugs 0.000 claims 1
XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 claims 1
239000007853 buffer solution Substances 0.000 abstract 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 54
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 38
UREBDLICKHMUKA-UHFFFAOYSA-N 9-fluoro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CO)(O)C1(C)CC2O UREBDLICKHMUKA-UHFFFAOYSA-N 0.000 description 20
229960000583 acetic acid Drugs 0.000 description 18
239000002246 antineoplastic agent Substances 0.000 description 17
239000012362 glacial acetic acid Substances 0.000 description 16
229940079593 drug Drugs 0.000 description 12
239000003814 drug Substances 0.000 description 12
239000000243 solution Substances 0.000 description 10
239000008280 blood Substances 0.000 description 9
210000004369 blood Anatomy 0.000 description 9
229940127089 cytotoxic agent Drugs 0.000 description 9
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 8
229940041181 antineoplastic drug Drugs 0.000 description 8
238000009472 formulation Methods 0.000 description 7
238000001990 intravenous administration Methods 0.000 description 7
OSFCMRGOZNQUSW-UHFFFAOYSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10h-acridine-4-carboxamide Chemical compound N1C2=C(OC)C=CC=C2C(=O)C2=C1C(C(=O)NC1=CC=C(C=C1)CCN1CCC=3C=C(C(=CC=3C1)OC)OC)=CC=C2 OSFCMRGOZNQUSW-UHFFFAOYSA-N 0.000 description 6
230000000259 anti-tumor effect Effects 0.000 description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 4
230000000973 chemotherapeutic effect Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
241000124008 Mammalia Species 0.000 description 3
238000002372 labelling Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
229960003529 diazepam Drugs 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000013583 drug formulation Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
229940068968 polysorbate 80 Drugs 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
101100130497 Drosophila melanogaster Mical gene Proteins 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
229920001304 Solutol HS 15 Polymers 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
241000863480 Vinca Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
150000001251 acridines Chemical class 0.000 description 1
229930183665 actinomycin Natural products 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
229960001220 amsacrine Drugs 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
229950010513 ditekiren Drugs 0.000 description 1
108010083220 ditekiren Proteins 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
229960003727 granisetron Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000003165 hydrotropic effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
229960005343 ondansetron Drugs 0.000 description 1
MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical group [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000009101 premedication Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000002461 renin inhibitor Substances 0.000 description 1
229940086526 renin-inhibitors Drugs 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
SASWSEQJAITMKS-JJNNLWIXSA-N tert-butyl (2s)-2-[[(2s)-1-[[(2s)-1-[[(4s,5s,7s)-5-hydroxy-2,8-dimethyl-7-[[(2s,3s)-3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]carbamoyl]nonan-4-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]p Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC=1N=CC=CC=1)C(C)C)N(C)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)OC(C)(C)C)C1=CN=CN1 SASWSEQJAITMKS-JJNNLWIXSA-N 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA002201628A 1994-10-05 1995-10-04 Parenteral pharmaceutical compositions containing gf120918a Abandoned CA2201628A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31830894A	1994-10-05	1994-10-05
US08/318,308		1994-10-05

Publications (1)

Publication Number	Publication Date
CA2201628A1 true CA2201628A1 (en)	1996-04-18

Family

ID=23237614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002201628A Abandoned CA2201628A1 (en)	1994-10-05	1995-10-04	Parenteral pharmaceutical compositions containing gf120918a

Country Status (12)

Country	Link
EP (1)	EP0784474A2 (de)
JP (1)	JPH10507177A (de)
KR (1)	KR970705997A (de)
AU (1)	AU702519B2 (de)
BR (1)	BR9509251A (de)
CA (1)	CA2201628A1 (de)
CZ (1)	CZ104197A3 (de)
HU (1)	HUT77883A (de)
NZ (1)	NZ295546A (de)
PL (1)	PL319511A1 (de)
RU (1)	RU2157687C2 (de)
WO (1)	WO1996011007A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ135199A3 (cs) *	1996-10-18	1999-09-15	Xenova Limited	Způsob přípravy N-/2-(dimethylamino)ethyl/akridin-4-karboxyamidu
GB9708805D0 (en)	1997-05-01	1997-06-25	Smithkline Beecham Plc	Compounds
GB9710612D0 (en) *	1997-05-23	1997-07-16	Glaxo Group Ltd	Synthesis of acridine derivatives
GB9810876D0 (en)	1998-05-20	1998-07-22	Smithkline Beecham Plc	Compounds
US5922754A (en) *	1998-10-02	1999-07-13	Abbott Laboratories	Pharmaceutical compositions containing paclitaxel
WO2000021951A1 (en)	1998-10-08	2000-04-20	Smithkline Beecham Plc	Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
AT408186B (de) *	1998-12-15	2001-09-25	Sanochemia Pharmazeutika Ag	Wässerige zubereitung von beta-carotin
DE60030283T2 (de)	1999-05-17	2007-09-20	Cancer Research Ventures Ltd.	Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
US6521635B1 (en)	2000-01-20	2003-02-18	The United States Of America As Represented By The Department Of Health And Human Services	Inhibition of MXR transport by acridine derivatives
JP2004501955A (ja) *	2000-06-30	2004-01-22	アイネックス　ファーマシューティカルズ　コーポレイション	リポソーム抗新生物薬剤およびその使用
US7122201B2 (en)	2001-06-28	2006-10-17	Baxter International Inc.	Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using surfactants and amino acids
RU2205634C1 (ru) *	2002-06-18	2003-06-10	Нестерук Владимир Викторович	Лекарственное средство, обладающее противорвотным действием
KR100866728B1 (ko) *	2004-11-12	2008-11-03	주식회사종근당	타크로리무스를 함유하는 주사제
FR2948568B1 (fr) *	2009-07-30	2012-08-24	Sanofi Aventis	Formulation pharmaceutique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4544657A (en) *	1983-05-19	1985-10-01	Hoffmann-La Roche Inc.	Substituted isoquinolines
KR100220538B1 (ko) *	1991-01-11	1999-09-15	뮈쉘 쥐르밀	아크리딘 유도체

1995
- 1995-10-04 CZ CZ971041A patent/CZ104197A3/cs unknown
- 1995-10-04 NZ NZ295546A patent/NZ295546A/xx unknown
- 1995-10-04 JP JP8512678A patent/JPH10507177A/ja active Pending
- 1995-10-04 BR BR9509251A patent/BR9509251A/pt not_active Application Discontinuation
- 1995-10-04 AU AU38913/95A patent/AU702519B2/en not_active Ceased
- 1995-10-04 HU HU9702291A patent/HUT77883A/hu unknown
- 1995-10-04 EP EP95938184A patent/EP0784474A2/de not_active Ceased
- 1995-10-04 CA CA002201628A patent/CA2201628A1/en not_active Abandoned
- 1995-10-04 RU RU97107466/14A patent/RU2157687C2/ru active
- 1995-10-04 PL PL95319511A patent/PL319511A1/xx unknown
- 1995-10-04 KR KR1019970702223A patent/KR970705997A/ko not_active Withdrawn
- 1995-10-04 WO PCT/US1995/012952 patent/WO1996011007A1/en not_active Ceased

Also Published As

Publication number	Publication date
BR9509251A (pt)	1997-10-21
EP0784474A2 (de)	1997-07-23
RU2157687C2 (ru)	2000-10-20
AU702519B2 (en)	1999-02-25
WO1996011007A1 (en)	1996-04-18
HUT77883A (hu)	1998-09-28
NZ295546A (en)	1999-01-28
PL319511A1 (en)	1997-08-18
AU3891395A (en)	1996-05-02
MX9702473A (es)	1997-07-31
CZ104197A3 (en)	1997-09-17
JPH10507177A (ja)	1998-07-14
KR970705997A (ko)	1997-11-03

Legal Events

Date	Code	Title	Description
2002-10-04	FZDE	Discontinued

Publication	Publication Date	Title
US10688111B2 (en)	2020-06-23	Liquid formulations of compounds active at sulfonylurea receptors
EP1052974B1 (de)	2009-05-20	Pharmazeutische zusammensetzung enthaltend epothilone
AU702519B2 (en)	1999-02-25	Parenteral pharmaceutical compositions containing GF120918A
US20080293796A1 (en)	2008-11-27	Parenteral and oral formulations of benzimidazoles
ES2451540T3 (es)	2014-03-27	Formas de dosificación oral de bendamustina
US11779585B2 (en)	2023-10-10	Method for treating coronavirus infections
BG66494B1 (bg)	2015-06-30	Методи за получаване на фармацевтични състави, съдържащи епотилонови аналози за лечение на рак
WO2018047074A1 (en)	2018-03-15	Sterile injectable compositions comprising drug micelles
EP2310009B1 (de)	2017-12-20	Parenteral und oral verabreichbare formulierungen aus benzimidazolen
EP1667656A1 (de)	2006-06-14	Zusammensetzungen und verfahren zur abgabe von biologisch wirksamen mitteln
AU2011273064A1 (en)	2012-11-22	Pharmaceutical compositions comprising paracetamol and process for preparing the same
EP2588097A2 (de)	2013-05-08	Pharmazeutische zusammensetzungen mit paracetamol und herstellungsverfahren dafür
RU2236227C1 (ru)	2004-09-20	Устойчивая фармацевтическая форма противоракового препарата
WO2012029076A2 (en)	2012-03-08	Stable pharmaceutical composition
MXPA97002473A (en)	1997-12-01	Parenteral pharmaceutical compositions containing gf1209
CN1164189A (zh)	1997-11-05	含有gf120918a的非肠道药物组合物
AU2024262981A1 (en)	2025-10-30	Injectable compositions of metolazone
WO2026078715A1 (en)	2026-04-16	Injectable composition of aprepitant
WO2024127418A1 (en)	2024-06-20	Injectable compositions of posaconazole
WO2026090749A1 (en)	2026-05-07	Pharmaceutical formulations comprising aprepitant
WO2025094002A1 (en)	2025-05-08	Lurbinectedin formulation
EP4025205A1 (de)	2022-07-13	Flüssige formulierungen von cabazitaxel
WO2018109731A1 (en)	2018-06-21	Pharmaceutical compositions of taxane and its derivatives
AU2004267882A1 (en)	2005-03-10	Compositions and methods for delivery of biologically active agents
HK1033809B (en)	2009-12-31	Pharmaceutical formulation containing epothilone